Business Context and Reporting Period
This Form 8-K was filed by OncoGenex Pharmaceuticals, Inc. on May 2, 2013. The filing serves to announce the Company's financial results for the first quarter of 2013. The registrant is incorporated in Delaware with principal executive offices in Bothell, Washington.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The document acts as a notification that a press release containing these details has been issued and is attached as Exhibit 99.1. Consequently, no quantitative financial metrics can be extracted from this specific text.
Material Changes
The filing does not detail specific material changes versus the prior comparable period within the body text. It references the issuance of a press release regarding Q1 2013 results, but the specific variances or trends are contained within the attached exhibit rather than this summary report.
Guidance, Outlook, and Risks
The text does not contain management commentary, forward-looking guidance, specific risk factors, or details on contingencies. It explicitly states that the information in Item 2.02 and Exhibit 99.1 is furnished and shall not be deemed "filed" for purposes of Section 18 of the Exchange Act, nor incorporated by reference except as expressly set forth.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated May 2, 2013) for actual Q1 2013 financial figures.
- Verify the discrepancy between the request metadata ("ACHIEVE LIFE SCIENCES, INC.") and the filing registrant ("ONCOGENEX PHARMACEUTICALS, INC.").
- Confirm whether the press release contains updated guidance or material risk disclosures not present in this 8-K summary.
- Check subsequent filings to see if the furnished information was later incorporated by reference.